Skip to main content
Clinical Trials/CTRI/2012/01/002347
CTRI/2012/01/002347
Not yet recruiting
Phase 4

Assessment of the efficacy and safety of the fixed-dose combination of levofloxacin plus cefpodoxime versus levofloxacin, cefpodoxime and amoxicillin/clavulanic acid monotherapy in patients with community acquired pneumonia and acute exacerbation of chronic bronchitis

Dr Sharif Tadvi0 sites80 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- community acquired pneumonia and acute exacerbation of chronic bronchitis
Sponsor
Dr Sharif Tadvi
Enrollment
80
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Sharif Tadvi

Eligibility Criteria

Inclusion Criteria

  • Subjects 18 \-65 years age of either sex who are able to give voluntary written informed consent and willing to come for follow up.
  • Patients with clinical signs and symptoms of CAP or AECB as per investigators discretion.
  • Chest X\-ray findings suggestive of CAP or AECB

Exclusion Criteria

  • Subjects requiring hospitalization
  • Subjects with known or suspected hypersensitivity to penicillins, levofloxacin, cefpodoxime or any the constituents of the formulation.
  • Subjects who have received antimicrobial therapy within 7 days prior to enrollment.
  • Patient who severe complications of RTI.
  • An uncontrolled, unstable clinically significant medical condition;
  • Clinically significant abnormal laboratory, vital sign or ECG findings at screening.
  • Pregnant and lactating females.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.
EUCTR2015-005155-27-HRKRKA-FARMA d.o.o.223
Active, not recruiting
Phase 1
Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and paranasal cavity and in patients with acute rhinitis – SeptaNazal DOUBLE clinical study.asal congestion in patients after nasal surgery or nasal cavities surgery and in patients with acute rhinitisMedDRA version: 19.0Level: HLTClassification code 10028736Term: Nasal congestion and inflammationsSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2015-005155-27-SIKrka, d.d., Novo mesto194
Recruiting
Phase 3
Evaluation of efficacy and tolerability of a fixed dose combination of Glucosamine sulphate and Omega 3 Fatty Acid For treatment of Painful Osteoarthritis of kneeHealth Condition 1: null- Painful osteoarthritis of Knee joint
CTRI/2010/091/000059Merck Limited210
Completed
Phase 3
A clinical Trial to study the effects of a fixed dose combination of diclofenac and eperisone hydrochloride with plain eperisone hydrochloride in patients with low back pai
CTRI/2010/091/002934Eisai Pharmaceuticals India Private Limited, 1st Floor, B-Wing, Marwah Centre, Krishanlal Marwah Marg, Andheri East, Mumbai - 400072240
Active, not recruiting
Not Applicable
Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens' syndromekeratoconjunctivitis siccaMedDRA version: 8.1Level: PTClassification code 10023350Term: Keratoconjunctivitis sicca
EUCTR2006-003391-35-NLaboratoires THEA